The Patented Medicine Prices Review Board launched consultations on the guidelines in the late fall. They did extend the period until mid-February. They are working with that feedback and have been engaging with industry, patient groups and others to ensure the guidelines reflect the regulations, the government's intent, and the concerns and interests of different stakeholder groups, including industry.
On March 11th, 2020. See this statement in context.